ArticleChemical communications (Cambridge, England)2018
Redox-responsive cisplatin nanogels for anticancer drug delivery.
Article in Chemical communications (Cambridge, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 51 citations in OpenAlex.
- Transforming cisplatin into targeted photothermal chemotherapeutics through the platinum-phosphate coordination within a hyaluronan nanogel.Science advances · 2026Article
- Polymer Network-Based Nanogels and Microgels: Design, Classification, Synthesis, and Applications in Drug Delivery.Gels (Basel, Switzerland) · 2025Review
- Biomedical Application of Nanogels: From Cancer to Wound Healing.Molecules (Basel, Switzerland) · 2025Review
- Review
- Excessive glutathione intake contributes to chemotherapy resistance in breast cancer: a propensity score matching analysis.World journal of surgical oncology · 2024Article
- Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers.Gels (Basel, Switzerland) · 2023Review
- Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review.RSC advances · 2023Review
- An Overview of Antitumour Activity of Polysaccharides.Molecules (Basel, Switzerland) · 2022Review
- Nanomedicines for Overcoming Cancer Drug Resistance.Pharmaceutics · 2022Review
- CuPharmaceutics · 2022Article
- Preparation and use of nanogels as carriers of drugs.Drug delivery · 2021Review
- Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery.Acta pharmaceutica Sinica. B · 2021Article
- Self-Assembled Nanogels Based on Ionic Gelation of Natural Polysaccharides for Drug Delivery.Frontiers in bioengineering and biotechnology · 2021Review
- Therapeutic polymeric nanomedicine: GSH-responsive release promotes drug release for cancer synergistic chemotherapy.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inspired by cisplatin's deactivation by glutathione (GSH) in cancer, a GSH responsive nanogel loaded with doxorubicin (Dox) was prepared using hyaluronan as a matrix and cisplatin as a crosslinker. The elevated GSH depletes the cisplatin crosslinker in the nanogel, enhances Dox release and boosts cytotoxicity, thus providing a new GSH responsive platform to reverse cisplatin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.